Navigation Links
Kendle Invites You to Attend its Second Quarter 2008 Earnings Conference Call and Webcast
Date:7/16/2008


CINCINNATI, July 16 /PRNewswire-FirstCall/ --

CALL DATE: Wednesday, Aug. 6, 2008

TIME: 9:30 a.m. Eastern Time

HOST: Dr. Candace Kendle, Chairman and CEO

Kendle (Nasdaq: KNDL) will conduct a telephone conference call and simultaneous webcast on Wednesday, Aug. 6 at 9:30 a.m. Eastern Time to discuss its financial results for the Second Quarter ended June 30, 2008. A question and answer session will follow.

Webcast Instructions

To access the live webcast, visit the company Web site at http://www.kendle.com or link to the Webcast directly at http://www.videonewswire.com/event.asp?id=50021 . Instructions for accessing the webcast are provided at both sites. The webcast will be archived at http://www.kendle.com (click on "Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on Sept. 5, 2008. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx .

Conference Call Instructions

To register (RSVP) for the telephone conference call, U.S. and Canadian participants should dial (800) 223-7104. Participants outside North America should dial (706) 645-6519.

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 399-0069. Participants outside North America should dial (706) 643-3694. A replay will be available through 5 p.m. Eastern Time on Sept. 5 by dialing (706) 645-9291 and entering conference ID number 55347808.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing drugs to market for the benefit of patients worldwide. As one of the fastest-growing global providers of Phase I-IV services, we offer experience spanning 90 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges. Kendle was named "Top CRO to Work With" in the Thomson CenterWatch 2007 survey of U.S. investigative sites and "Best CRO" for 2007 and 2006 by leading global pharmaceutical publication Scrip World Pharmaceutical News.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 1200, Cincinnati, OH 45202 or from the company's Web site at http://www.kendle.com.

(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )


'/>"/>
SOURCE Kendle International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Host Conference Call and Webcast to Discuss DecisionLine Acquisition and Provide Update on Second Quarter Progress
2. Kendle Expands Global Clinical Pharmacology Capabilities with Acquisition of DecisionLine Clinical Research Corporation
3. Kendle Appoints Patricia Williams Vice President, Commercial Operations
4. Kendle Invites You to Attend its First Quarter 2008 Earnings Conference Call and Webcast
5. Kendle to Present at the Lehman Brothers Eleventh Annual Global Healthcare Conference
6. Kendle Leaders Adopt 10b5-1 Trading Plans
7. Kendle to Present at the 29th Annual Raymond James Institutional Investors Conference
8. Kendle Hires Satish Tripathi, PhD, RAC as Vice President, Global Regulatory and Quality
9. Kendle to Present at the Wachovia 2008 Healthcare Conference
10. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
11. Kendle Named Best CRO for Second Consecutive Year by Leading Global Pharmaceutical Publication Scrip
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created 4Sight Medical ... to the healthcare market. The company's primary focus is on new product introductions, ... strategies that are necessary to help companies efficiently bring their products to market. ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young ... cancer. Members of the Class of 2016 were selected from a pool of ... More About the Class of 2016 PCF Young Investigators ... ... ...
Breaking Biology Technology:
(Date:4/19/2016)... DUBAI , UAE, April 20, 2016 ... can be implemented as a compact web-based "all-in-one" system ... in the biometric fingerprint reader or the door interface ... requirements of modern access control systems. The minimal dimensions ... the ID readers into the building installations offer considerable ...
(Date:4/14/2016)... , April 14, 2016 ... and Malware Detection, today announced the appointment of ... the new role. Goldwerger,s leadership appointment comes ... the heels of the deployment of its platform at ... behavioral biometric technology, which discerns unique cognitive and physiological ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):